Plasma biomarkers that reflect specific amyloid beta (Abeta) proteoforms provide an insight in the treatment effects of Alzheimer’s disease (AD) therapies. Our aim was to develop and validate ready-to-use Simoa ‘Amyblood’ assays that measure full length Abeta1-42 and Abeta1-40 and compare their performance with two commercial assays. Linearity, intra- and inter-assay %CV were compared between Amyblood, Quanterix Simoa triplex, and Euroimmun ELISA. Sensitivity and selectivity were assessed for Amyblood and the Quanterix triplex. Clinical performance was assessed in CSF biomarker confirmed AD (n = 43, 68 ± 6 years) and controls (n = 42, 62 ± 5 years). Prototype and Amyblood showed similar calibrator curves and differentiation (20 AD vs 20 controls, p < 0.001). Amyblood, Quanterix triplex, and ELISA showed similar linearity (96%-122%) and intra-assay %CVs (≤ 3.1%). A minor non-specific signal was measured with Amyblood of + 2.4 pg/mL Abeta1-42 when incubated with 60 pg/mL Abeta1-40. A substantial non-specific signal of + 24.7 pg/mL Abetax-42 was obtained when 40 pg/mL Abeta3-42 was measured with the Quanterix triplex. Selectivity for Abeta1-42 at physiological Abeta1-42 and Abeta1-40 concentrations was 125% for Amyblood and 163% for Quanterix. Amyblood and Quanterix ratios (p < 0.001) and ELISA Abeta1-42 concentration (p = 0.025) could differentiate AD from controls. We successfully developed and upscaled a prototype to the Amyblood assays with similar technical and clinical performance as the Quanterix triplex and ELISA, but better specificity and selectivity than the Quanterix triplex assay. These results suggest leverage of this specific assay for monitoring treatment response in trials.
Alzheimer’s disease (AD) is the most common form of dementia, affecting 50 million people worldwide1 In vivo AD diagnosis and monitoring of treatment response in clinical trials is based on changes in amyloid beta proteins (Abeta), measured by positron emission tomography (PET) or in cerebrospinal fluid (CSF)2,3,4 However, both methods are associated with major disadvantages in terms of high costs (PET) and invasiveness (lumbar puncture to collect CSF), which prohibit repetitive analysis. Therefore, it is critical to have access to blood-based biomarkers as a less invasive method for monitoring of treatment effects.
Since the introduction of highly sensitive technologies such as bead-based immunoassays or immunoprecipitation combined with mass spectrometry (IP-MS), consistent reductions in plasma Abeta42/40 ratio are reported in AD5,6,7,8,9,10 With IP-MS, a 10–15% reduction in the plasma Abeta42/40 ratio has been measured in amyloid PET or CSF positive cases, compared to amyloid negative cases7, and the ratio could differentiate the groups with an area under the curve (AUC) of 84–97%8 IP-MS is often more sensitive than immunoassays, but requires a high sample volume and a high level of expertise which may limit broad clinical implementation. The Abeta42/40 ratio measured with the Single Molecule Array (Simoa, Quanterix)11, showed promising results in identifying individuals with amyloid pathology (AUC of 68–87%5,9) across controls, mild cognitive impairment (MCI), and AD. This bead-based technology offers high throughput and is ultrasensitive. However, the commercial Quanterix assay lacks antibody specificity, since it measures Abetax-42 and Abetax-40, whereas the specificity for full-length Abeta1-42 and Abeta1-40 is important to understand the effect of treatments that target specific Abeta isoforms12.
At Amsterdam University Medical Centers (Amsterdam UMC) and ADx Neurosciences (ADx) novel ready to use (RTU) immunoassays, called “Amyblood”, were developed for detection of full length Abeta1-42 and Abeta1-40 with Simoa technology13 This way both the high specificity of the antibodies and the high sensitivity of Simoa technology could be leveraged. The aim of the present study is to analytically validate the Amyblood assays, including specificity and selectivity evaluation, and explore their clinical value in a CSF-biomarker confirmed cohort of AD patients and controls. We compared the analytical and clinical performance of the Amyblood assays with the commercially available Quanterix triplex kit (Abetax-42/Abetax-40) and the Euroimmun ELISA assays (Abeta1-42/Abeta1-40).
Robustness of the upscaled Amyblood RTU assays
Differences in antibody lot were determined by comparing three lots of ADx102 and ADx103 conjugated bead batches. The variation in AEB values of the calibrator across the lots was 19%CV for Abeta1-42 and 14% for Abeta1-40 (eFigure 1). The calibration curves %CV of the small and upscaled bead batches based on calibrator AEB values was 10.0% (range: 3.8%-17.6%) for Abeta1-42 (eFigure 2A) and 7.0% (range: 0.03%-13.9%) for Abeta1-40 beads (eFigure 2B). Amyblood Abeta1-42/1–40 inter-assay %CV was 2.9% (sample 1: 3.9% at AUMC, 3.5% ADx, sample 2: 2.2% at AUMC, 2.0% at ADx) and inter-center %CV was 17.2% (sample 1: 14% at AUMC, 23% ADx, sample 2: 14% at AUMC, 13% at ADx) (eFigure 3).
For proof of concept, the Abeta1-42 and Abeta1-40 concentrations were measured in a sample set of 20 CSF Abeta1-42 positive AD cases and 20 CSF Abeta1-42 negative SCD cases in both these upscaled versions and the prototype assays that were basis for these upscaled assays. This prototype assay (supplementary methods) developed in-house by Amsterdam UMC similarly utilized the capture antibodies ADx10214 for Abeta1-42 or ADx10314 for Abeta1-40 and detector antibody ADx10114 for Abeta1 (ADx, Ghent, BE). The fold change in Abeta1-42/1–40 ratio between AD and controls was 1.39 for the prototype and 1.29 for the Amyblood (both: p < 0.001, Fig. 1). There was a good correlation between the prototype and Amyblood results of Abeta1-42 (R = 0.77, p < 0.001), Abeta1-40 (R = 0.89, p < 0.001), and the Abeta1-42/1–40 ratio (R = 0.69, p = 0.001) (eFigure 4).
Analytical validation of all six assays in this study
Upon serial dilution, all six Abeta assays showed acceptable linearity (i.e. in the range 80–120%), except for a small deviation of the Quanterix Abetax-42 assay (122%) (eTable 1). All assays showed intra-assay %CV values < 10% for clinical samples. The inter-assay %CV of the Amyblood Abeta1-42 assay was 13.3%, and 10.4% for Abeta1-40. The inter-assay %CV of Quanterix Abetax-42 assay was 7.9%, and 5.4% for Abetax-40. The LLOQ’s were 1.6 pg/mL for Amyblood Abeta1-42 and 1.7 pg/mL for Abeta1-40; 0.34 pg/mL for Quanterix Abetax-42 and 0.16 pg/mL for Abetax-40; and 5.4 pg/mL for ELISA Abeta1-42 and 11.9 pg/mL for Abeta1-40. One sample measured with the Amyblood Abeta1-42 assay and eight samples measured with the ELISA Abeta1-42 assay were lower than their blank. All Abeta40 concentrations were above the blank (eFigure 5).
Assay specificity and selectivity
Selectivity and specificity of the Abeta42 and Abeta40 measurements were tested for the Amyblood and Quanterix assays. Detailed specificity concentrations and %recovery are described in eTables 2 and 3. Different spike concentrations were used for the Amyblood and Quanterix assays, to align with their difference in absolute Abeta42 and Abeta40 concentrations (eTable 4).
Specificity of the Amyblood and Quanterix assays
Low, medium and high concentrations of Abeta fragments 1–42, 1–40, 1–43, 2–42, and 3–42 spiked in sample buffer were measured with the Abeta1-42 and Abetax-42 assays. For Amyblood, a minor signal above blank was measured when other Abeta fragments were incubated, with a maximum reported result of 2.4 pg/mL for 60 pg/mL of spiked Abeta1-40 (Fig. 2A). A substantial increase compared to the blank was observed for Quanterix Abetax-42 values, especially for Abeta2-42, and Abeta3-42 fragments, with a maximum of + 24.7 pg/mL Abetax-42 for 40 pg/mL of Abeta3-42 (Fig. 2B). When measuring Abeta fragments 1–42, 1–38, 1–39, and 11–40 with the Amyblood Abeta1-40 and Quanterix Abetax-40 assays, none of the other Abeta isoforms yielded a signal above blank. The Abeta 1–40 fragment was accurately measured with the Amyblood assay, but yielded a lower formal concentration when measured with the Quanterix assay (Fig. 2C and D).
Selectivity of the Amyblood and Quanterix assays
We tested selectivity by measuring the signal of one analyte in sample diluent (either Abeta1-42 or Abeta1-40), in the presence of a known concentration of the other analyte. Described physiological concentrations were based on concentrations measurements in plasma after sample dilution (eTable 4).
For the Amyblood assay, the %recovery of 6 pg/mL Abeta1-42 measured with the Amyblood assay increased from 115% in the presence of the low concentration (3 pg/mL) of Abeta1-40 to 154% for the high concentration (60 pg/mL) of Abeta1-40. The %recovery of 25 pg/mL Abeta1-42 was 89% in presence of the low and 105% for in the presence of the high concentration Abeta1-40. The %recovery of 60 pg/mL Abeta1-42 was 101% in the presence of the low and 105% in the presence of the high Abeta1-40 concentration. At 6 pg/mL Abeta1-42 and 15 pg/mL Abeta1-40, which approximate the physiological concentrations measured in plasma after correction for dilution factor, the %recovery of Abeta1-42 was 125% (Fig. 3A).
For the Quanterix assay, the %recovery of 1 pg/mL plasma Abetax-42 measured with the Quanterix assay increased from 105% in the presence of the low concentration (4 pg/mL) Abeta1-40 to 1021% in the presence of the high concentration (130 pg/mL) Abeta1-40. The %recovery of 15 pg/mL Abeta1-42 was 96% in the presence of a low and 188% in the presence of a high concentration of Abeta1-40. The %recovery of 40 pg/mL Abeta1-42 was 88% in the presence of the low concentration of Abeta1-40 and 140% in the presence of the high Abeta1-40 concentration. At 1 pg/mL Abeta1-42 and 25 pg/mL Abeta1-40, which approximate the physiological concentrations, the %recovery of Abeta1-42 was 163% (Fig. 3B). For both Abeta42 assays, the increase in %recovery returned to normal upon increasing Abeta42 concentrations relative to the Abeta40 concentration.
The %recovery of 3 pg/mL plasma Abeta1-40 measured with the Amyblood assay was 113% for the low concentration (6 pg/mL) Abeta1-42 and 110% for the high concentration (60 pg/mL) Abeta1-42. The %recovery of 15 pg/mL Abeta1-40 was 110% for the low and 95% for the high concentration Abeta1-42. The %recovery of 60 pg/mL Abeta1-40 was 102% for the low and 96% for the high Abeta1-42. At physiological concentrations of 15 pg/mL Abeta1-40 and 6 pg/mL Abeta1-42 the %recovery of Abeta1-40 was 110% (Fig. 3C).
The %recovery of 4 pg/mL plasma Abetax-40 measured with the Quanterix assay was 89% for the low concentration (1 pg/mL) Abeta1-42 and 92% in the presence of the high concentration (40 pg/mL) Abeta1-42. The %recovery of 25 pg/mL Abeta1-40 was 94% in the presence of the low and 97% in presence of the high concentration Abeta1-42. The %recovery of 130 pg/mL Abeta1-40 was 112% for the low and 106% for the high concentration Abeta1-42. The highest %recovery was 115%, found at 130 pg/mL Abeta1-40 and 15 pg/mL Abeta1-42. At physiological concentrations of 25 pg/mL Abeta1-40 and 1 pg/mL Abeta1-42 the %recovery of Abetax-40 was 94% (Fig. 3D). The %recovery of both Abeta40 assays seems relatively unaffected by an increase in Abeta42.
Assay validation in clinical samples
Plasma Abeta42 was reduced in AD patients compared to controls for all three assays: -8.5% for Amyblood (uncorrected: p = 0.075; corrected for age, sex, storage time, and sample run: p = 0.012), -3.6% for Quanterix (uncorrected p = 0.096, corrected p = 0.005), and -9.5% for ELISA (uncorrected p = 0.008, corrected p = 0.025). There were no differences in plasma Abeta40 levels between AD patients and controls after correction for the indicated covariates: Amyblood; uncorrected: p = 0.023; corrected: p = 0.98, Quanterix: uncorrected: p = 0.16, corrected: p = 0.96, ELISA: uncorrected: 0.06, corrected: 0.62 (eTable 4, eFigure 6). The Amyblood Abeta1-42/1–40 ratio was decreased by -21% in AD patients compared to controls (p < 0.001 uncorrected, corrected p < 0.001). The Quanterix Abetax-42/x-40 ratio was decreased by -13% (uncorrected p = 0.001, corrected p < 0.001). The ELISA Abeta1-42/1–40 ratio was decreased by -22% (uncorrected p = 0.004, corrected p = 0.24). Excluding a Abeta1-42/1–40 ELISA outlier that was 3.9 times the median ratio for controls from the statistical analysis changed the p-values for the ELISA analyses (uncorrected p < 0.001, corrected p = 0.06) (Fig. 4).
Correlations of results of the three immuno-assays
The plasma Amyblood Abeta42 concentrations correlated with the Quanterix and ELISA Abeta42 results (ρ > 0.48, p < 0.001) (Fig. 5A and B). Amyblood Abeta40 concentrations correlated with the Quanterix and ELISA Abeta40 results (ρ > 0.74, p < 0.001) (Fig. 5C and D). The Amyblood Abeta42/40 ratio correlated with the Quanterix ratio (ρ = 0.68, p < 0.001), not with the ELISA ratio (ρ = -0.01, p = 0.95) (Fig. 5E and F).
The CSF Abeta1-42 concentrations did not correlate with plasma Abeta42 measured with Amyblood (ρ = 0.10, p = 0.36), Quanterix (ρ = 0.11, p = 0.32) or ELISA (ρ = 0.25, p = 0.09), whereas the CSF Abeta1-42 concentrations did correlate with the Abeta42/40 ratio, measured with Amyblood (ρ = 0.25, p = 0.02), Quanterix (ρ = 0.28, p = 0.01) and ELISA (ρ = 0.36, p = 0.001).
With this study we introduce the novel Amyblood assays developed on ultrasensitive Simoa technology for detection of the specific N-terminal Abeta peptides Abeta1-42 and Abeta1-40 in plasma. The validation was successful and the results were highly comparable to technical and clinical validation results obtained for two commercially available assays: the Quanterix triplex and Euroimmun ELISA. The specificity of the Amyblood assays for the specific isoforms was higher compared to the Quanterix assay. Moreover, the Amyblood Abeta1-42/1–40 ratio could successfully differentiate AD cases from controls, similar to the Quanterix assay. The ELISA ratio could not differentiate the groups, though the ELISA Abeta1-42 concentration by itself could. Our validation data show that the Amyblood assays are suitable for robust measurement of 1–42 and 1–40 amyloid isoforms in plasma.
The development of the Amyblood assays was motivated by the need for an assay that simultaneously offers high specificity, high sensitivity and high throughput. Therefore, we employed the known specificity of the ADx102, ADx103, and ADx101 antibodies as demonstrated earlier in CSF,15,16 together with the sensitivity of the Simoa technology11. The promising prototype assay results (eFigure 3) urged us to upscale for widespread validation. Upscaling is challenging since production of larger stock volumes can influence the reagent performance and may affect the sensitivity. Therefore, performance of the prototype and upscaled batch were thoroughly tested. Upscaling did not affect the calibrator curve, reproducibility was demonstrated at Amsterdam UMC and ADx (variation < 20%), and lastly, the assay remained successful in differentiating 20 AD patients and 20 controls (p < 0.001). These results indicate that the transformation of our initial prototype to the RTU Amyblood assays was successful.
Our specificity and sensitivity analyses were performed for the Amyblood and Quanterix assays only, since the Amyblood and Euroimmun assays use the same antibodies, but the bead-based Simoa platform can reach higher sensitivity than ELISA. The specificity analyses showed that the Amyblood Abeta1-42 assay showed minor cross-reactivity for other proteoforms in sample buffer. At 60 pg/ml Abeta1-40 in sample diluent, a non-specific concentration of 2.4 pg/mL was measured with the Amyblood Abeta1-42 assay. However, this nonspecific signal could be clinically meaningful, being similar to the group difference of also 2.4 pg/mL Abeta1-42 as observed between AD and controls. With the Quanterix Abetax-42 assay, a non-specific signal of 0.9 pg/mL was read at 40 pg/mL Abeta1-40, which is three times the group difference of 0.3 pg/mL Abetax-42 as measured with this assay. In addition, a minor increase of 0.8 fold the group difference was measured with the Amyblood Abeta1-42 assay when Abeta3-42 in sample buffer was incubated, where a large increase of 80 fold the group difference was measured with the Quanterix Abetax-42 assay for this proteoform. The difference in assay specificity could be explained by the Amyblood N-terminal ADx102 (21F2) antibody that is specific for the first amino acid of the Abeta peptide, whereas the Quanterix assay detects N-terminal amino acid 4–10. However, our specificity experiments were performed in sample buffer, whereas a wide variety of endogenous proteins are present in plasma which would make low affinity non-specific binding less likely17. Indeed, our selectivity analyses showed a recovery closer to 100% for Amyblood Abeta1-42 for higher Abeta1-42 concentrations next to the presence of varying concentrations of Abeta1-40 peptide. At physiological concentrations of Abeta1-42 and Abeta-40 in buffer, the %recovery was 125% for Abeta1-42. For the Quanterix assay, the Abetax-42 recovery was higher (163%) at physiological concentrations. Our data suggest that the Amyblood Abeta1-42 assay had better specificity and selectivity than the Quanterix Abetax-42 assay. Finally, there was no cross reactivity for both Abeta40 assays, indicating the high specificity of the 2G3 antibody for Abeta40 employed in both formats. Exactly knowing which proteoform is measured as compared to measuring a mixture of full-length and truncated proteoforms might be preferred in clinical trials that target Abeta1-4212, to be able to specifically map target engagement.
The Amyblood and Quanterix assays could successfully differentiate CSF Abeta1-42 positive AD patients and Abeta1-42 negative controls. We found that the ELISA ratio could not differentiate AD from controls, but the ELISA Abeta1-42 concentration alone could. A recent study comparing the performance of the Abeta1-42/1–40 ratio measured with the Amyblood assays and Euroimmun ELISA in non-demented elderly found that both assays could differentiate between amyloid-PET positive and negative participants with similar accuracy18. Other studies have also shown that ELISA Abeta42 or the Abeta42/40 ratio could differentiate between amyloid positive (either by CSF or PET) and negative participants18,19,20,21,22,23,24,25. Similar to other studies, we found no correlation between CSF Abeta1-42 and plasma Abeta42 concentrations, and only a weak correlation with the plasma Abeta1-42/1–40 ratio5,6,20,25. An explanation could be that amyloid produced peripherally, for example by platelets26, distorts the association of Abeta measured in plasma with Abeta produced only by the central nervous system, as measured in CSF. In the CSF, the full length Abeta1-42 and Abeta1-40 proteoforms and not the n-truncated forms are measured on widely used (automated) platforms to support the specific diagnosis of AD (e.g., Fujirebio Lumipulse, Roche Elecsys). For comparability reasons, it is be preferred to measure this same full-length Abeta1-42 and Abeta1-40 isoforms in blood.
It has been suggested that SCD cases have a higher risk of converting to AD compared to healthy elderly controls27. We carefully selected controls with normal CSF biomarker values, who are not likely to convert28. We wish to stress that the focus of our study was to compare analytical performance and clinical samples were included to indicate potential clinical value, since other studies are conducted on early diagnostic use of the Amyblood assays18,29,30.
A next step in the development of these assays is to leverage the multiplexing possibilities of Simoa technology and simultaneously detect multiple biomarkers, to reflect different aspects of AD within one assay run, saving time and resources. It is to note, that the results presented in this study, together with the conducted diagnostic Amyblood studies18,29,30, resulted in the development of the neurology 4-plex E assay kit by Quanterix, incorporating the Amyblood assays together with the glial fibrillary acidic protein and neurofilament light assays. This availability enables independent and widespread validation. In addition, development of Certified Reference Material is critical to calibrate and compare different amyloid assays and to enable clinical implementation.
We have developed an exceptionally specific blood test that measures full length Abeta1-42 and Abeta1-40 using high throughput semi-automated ultrasensitive technology. This study shows that the Amyblood assay has the potential to specifically and sensitively measure the concentrations of full length Abeta1-42 and Abeta1-40, and as such could be a specific test for target engagement in future clinical trials.
Prototype and Amyblood assay development and transfer
For proof of concept, a prototype assay (supplementary methods) was developed in-house by Amsterdam UMC using a Simoa homebrew assay development kit (Quanterix, MA), utilizing capture antibodies ADx102 (21F12)14 for Abeta1-42 or ADx103 (2G3)14 for Abeta1-40 and detector antibody ADx101 (3D6)14 for Abeta1 (ADx, Ghent, BE). These prototype assays formed the basis for the Amyblood assays that were further developed and upscaled by ADx. The sample diluent formulation and capture antibody conjugation were optimized to improve sensitivity. Reproducibility in %CV was tested on 3 monoclonal antibody lots and on the small batch compared to the upscaled RTU assays (volumes equivalent to 50 assay kits of 96 data points) based on duplicate measurements of the average enzyme per bead (AEB) signal, excluding the blank. Inter- and intra-assay variation were tested in six independent runs by ADx and five runs at Amsterdam UMC based on duplo measurements of two plasma quality control samples. Initial clinical performance of the Abeta1-42/1–40 ratio was confirmed in 20 CSF Abeta1-42 positive AD cases and 20 CSF Abeta1-42 negative controls. Subsequently, the Amyblood RTU kits were shipped to Amsterdam UMC for further assay characterization and clinical validation. The Amyblood reagent preparation and assay set-up are detailed in the Supplementary methods.
Analytical characterization of the six assays
Analytical validation in all six assays (Abeta42 and Abeta40 measured with Amyblood, Quanterix, and ELISA) included measurement of the Lower Limit of Quantification (LLOQ) (mean of 16 blanc samples + 10 standard deviations (SD)), linearity upon dilution (15 EDTA plasma samples, three dilutions: dilution factor (df) 4, 6 and 8 for Abeta1-42 and df 8, 10, and 12 for Abeta1-40), intra-assay %CV (SD of duplicate measurement divided by the mean *100%) of 85 clinical samples and inter-assay %CV of 14 samples over two runs. Additionally, selectivity and specificity were investigated, including physiological, low, medium and high concentrations, detailed in the Supplementary methods.
Comparison of analytical assay characteristics
To compare the analytical performance of the novel Amyblood assays, we selected two commercially available plasma amyloid immunoassays. The Quanterix Neurology 3-plex A assay kit employs the Simoa HD-1 analyzer, with a different capture antibody for Abetax-42 (H31L21) and the same capture antibody for Abetax-40 (2G3), combined with a different detector antibody (6E10), comprising the RHD motif (aa5-7) that is not N-terminus specific and therefore results in binding of x-42 and x-4031. We also selected the Euroimmun ELISA assays that employ the same antibodies as the Amyblood assays to measure Abeta1-42 and Abeta1-40. The Quanterix and ELISA analytical validation methods are specified in the Supplementary methods.
We included 85 participants from the Amsterdam Dementia Cohort32 with available EDTA plasma samples in the Biobank, 43 were AD dementia patients and 42 controls (n = 35 with subjective cognitive decline (SCD), n = 7 with psychiatric disease). All subjects visited the Alzheimer Center of the Amsterdam UMC between August 2002 and January 2017 for extensive dementia screening that consisted of neurological, physical, and neuropsychological evaluation, electroencephalography, brain magnetic resonance imaging, and CSF AD biomarker analysis32. The diagnosis was made upon multidisciplinary consensus based on applicable clinical criteria3,33. CSF Abeta1-42, P-tau181, and T-tau were measured using Innotest ELISA (Fuijirebio, Ghent, BE) by research staff blinded for clinical diagnoses34. CSF Abeta1-42 concentrations were adjusted for the drift in CSF biomarker analyses that occurred over the years and subsequently dichotomized as CSF amyloid positive (≤ 813 pg/ml Abeta1-42) and amyloid negative (> 813 pg/ml Abeta1-42)35. All AD-dementia cases were selected to be CSF amyloid positive, and all controls were required to be CSF amyloid negative (Table 1).
EDTA-plasma samples were obtained through venipuncture. After 10-min centrifugation at 1800xg within 2 h, plasma was aliquoted in 0.5 mL polypropylene tubes and stored at − 80 °C. Samples were thawed at room temperature and centrifuged at 14,000xg prior to analyses.
Written informed consent to use medical data and biomaterials for research purposes was in place. These and the experimental protocol were in accordance with and approved by the Amsterdam UMC ethical committee, location VUmc, and in accordance with the Helsinki Declaration act of 1975.
Plasma amyloid measurement
Abeta1-42 and Abeta1-40 were measured with the Amyblood kit on the Simoa HD-1 analyzer and by Euroimmun ELISA. Concentrations of Abetax-42 and Abetax-40 were measured with the Neurology 3-Plex assay A (Quanterix) on the Simoa HD-1 analyzer. All samples were manually diluted (eTable 1) and analyzed in duplicate, following manufacturer’s instructions.
Differences in Abeta42 and Abeta40 concentrations between patients with AD and controls were tested with linear regression analysis for group differences, both unadjusted and adjusted for sample storage time, sample run, age, and sex. The Abeta42/40 ratios measured with the Amyblood and Quanterix assays were normally distributed. The Abeta42/40 ratios measured with the ELISA assay were not normally distributed, neither after natural log transformation, nor after excluding the extreme outlier. Therefore, Spearman correlations were used to investigate all correlations. P < 0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics, version 26 and graphs were constructed using R version 3.5.3.
Ethical approval and consent to participate
Written consent to use medical data and biomaterials for research purposes was in place, in accordance with the ethical committee of the Amsterdam UMC, location VUmc, and with the Helsinki Declaration act of 1975.
Consent for publication
All authors approved this manuscript for publication.
The datasets used and analyzed during the current study can be made available by the corresponding author upon reasonable request.
Average enzyme per bead
Area under the curve
Lower Limit of Quantification
Mild Cognitive Impairment
Positron Emission Tomography
Ready to use
Subjective Cognitive Decline
Patterson, C. World Alzheimer report 2018. Alzheimer's Disease International (ADI), London (2018).
Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286–1294. https://doi.org/10.1001/jama.2019.2000 (2019).
Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14, 535–562. https://doi.org/10.1016/j.jalz.2018.02.018 (2018).
Lewczuk, P. et al. Cerebrospinal fluid Aβ42/40 corresponds better than aβ42 to amyloid PET in alzheimer’s disease. J. Alzheimers Dis. 55, 813–822. https://doi.org/10.3233/jad-160722 (2016).
Janelidze, S. et al. Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci. Rep. 6, 26801. https://doi.org/10.1038/srep26801 (2016).
Verberk, I. M. W. et al. Plasma amyloid as prescreener for the earliest alzheimer pathological changes. Ann. Neurol. 84, 648–658. https://doi.org/10.1002/ana.25334 (2018).
Ovod, V. et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers. Dement. 13, 841–849. https://doi.org/10.1016/j.jalz.2017.06.2266 (2017).
Nakamura, A. et al. High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554, 249–254. https://doi.org/10.1038/nature25456 (2018).
Li, W. W. et al. Brain amyloid-beta deposition and blood biomarkers in patients with clinically diagnosed alzheimer’s disease. J. Alzheimers. Dis. 69, 169–178. https://doi.org/10.3233/JAD-190056 (2019).
Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for alzheimer disease-related beta-amyloid status. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.1632 (2019).
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599. https://doi.org/10.1038/nbt.1641 (2010).
Izzo, N. J. et al. Alzheimer’s therapeutics targeting amyloid beta 1–42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS ONE 9, e111898. https://doi.org/10.1371/journal.pone.0111898 (2014).
QuanterixCorp. Whitepaper 5.0 - Enabling Ultrasensitive Protein Quantification with the Quanterix Homebrew Kit. (2014).
Johnson-Wood, K. et al. Amyloid precursor protein processing and Ab42 deposition in a transgenic mouse model of Alzheimer disease. Natl. Acad. Sci. USA 94, 1550–1555 (1997).
Struyfs, H. et al. Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J. Alzheimers. Dis. 45, 813–822. https://doi.org/10.3233/JAD-141986 (2015).
Vanderstichele, H. M. et al. Optimized standard operating procedures for the analysis of cerebrospinal fluid abeta42 and the ratios of abeta isoforms using low protein binding tubes. J. Alzheimers. Dis. 53, 1121–1132. https://doi.org/10.3233/JAD-160286 (2016).
Kratz, A., Ferraro, M., Sluss, P. M. & Lewandrowski, K. B. Case records of the Massachusetts General Hospital Weekly clinicopathological exercises Laboratory reference values. New England J. Med. 351, 1548–1563. https://doi.org/10.1056/NEJMcpc049016 (2004).
De Meyer, S. et al. Comparison of ELISA- and SIMOA-based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis. Alzheimers Res. Ther 12, 162. https://doi.org/10.1186/s13195-020-00728-w (2020).
Doecke, J. D. et al. Total Abeta42/Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology 94, e1580–e1591. https://doi.org/10.1212/WNL.0000000000009240 (2020).
Albani, D. et al. Plasma Abeta42 as a biomarker of prodromal alzheimer’s disease progression in patients with amnestic mild cognitive impairment: evidence from the pharmaCog/E-ADNI study. J. Alzheimer’s Dis. JAD 69, 37–48. https://doi.org/10.3233/JAD-180321 (2019).
de Rojas, I. et al. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res. Ther. 10, 119. https://doi.org/10.1186/s13195-018-0444-1 (2018).
Perez-Grijalba, V. et al. Plasma abeta42/40 ratio detects early stages of alzheimer’s disease and correlates with CSF and neuroimaging biomarkers in the AB255 study. J. Prev. Alzheimers. Dis. 6, 34–41. https://doi.org/10.14283/jpad.2018.41 (2019).
Risacher, S. L. et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimers Dement (Amst) 11, 510–519. https://doi.org/10.1016/j.dadm.2019.05.007 (2019).
Fandos, N. et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 8, 179–187. https://doi.org/10.1016/j.dadm.2017.07.004 (2017).
Feinkohl, I. et al. Plasma amyloid concentration in alzheimer’s disease: performance of a high-throughput amyloid assay in distinguishing alzheimer’s disease cases from controls. J. Alzheimer’s Dis. JAD 74, 1285–1294. https://doi.org/10.3233/JAD-200046 (2020).
Humpel, C. Platelets: their potential contribution to the generation of beta-amyloid plaques in Alzheimer’s disease. Curr. Neurovasci. Res. 14, 290–298. https://doi.org/10.2174/1567202614666170705150535 (2017).
Slot, R. E. R. et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement 15, 465–476. https://doi.org/10.1016/j.jalz.2018.10.003 (2019).
Ebenau, J. L. et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology 95, e46–e58. https://doi.org/10.1212/WNL.0000000000009724 (2020).
Verberk, I. M. W. et al. Combination of plasma amyloid beta(1–42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther 12, 118. https://doi.org/10.1186/s13195-020-00682-7 (2020).
Chatterjee, P. et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl. Psychiatry https://doi.org/10.1038/s41398-020-01137-1 (2021).
Baghallab, I., Reyes-Ruiz, J. M., Abulnaja, K., Huwait, E. & Glabe, C. Epitomic characterization of the specificity of the anti-amyloid abeta monoclonal antibodies 6E10 and 4G8. J. Alzheimers. Dis. 66, 1235–1244. https://doi.org/10.3233/JAD-180582 (2018).
van der Flier, W. M. & Scheltens, P. Amsterdam dementia cohort: performing research to optimize care. J. Alzheimers Dis. 62, 1091–1111. https://doi.org/10.3233/JAD-170850 (2018).
Jessen, F. et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers. Dement. 10, 844–852. https://doi.org/10.1016/j.jalz.2014.01.001 (2014).
Mulder, C. et al. Amyloid-beta(1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem. 56, 248–253. https://doi.org/10.1373/clinchem.2009.130518 (2010).
Tijms, B. M. et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-beta 1–42 analysis results. Clin. Chem. 64, 576–585. https://doi.org/10.1373/clinchem.2017.281055 (2018).
Elisabeth Thijssen is supported by a TKI research grant from Health Holland (LSHl17OO1). Inge Verberk is supported by research grants Gieskes-Strijbis Fonds and Alzheimer Nederland (NL-17004). Charlotte Teunissen is supported by the European Commission (Marie Curie International Training Network, JPND), the Dutch Research Council (ZonMW), The Weston Brain Institute, Alzheimer Netherlands. Wiesje van der Flier holds the Pasman chair, and is recipient of NCDC, which is funded in the context of Deltaplan Dementie from ZonMW Memorabel (projectnr 73305095005) and Alzheimer Nederland. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. This research is performed in close collaboration with ADx NeuroSciences, Ghent, Belgium. Funding agencies had no role in the design and conduct of the study, collection, management, analysis or interpretation of the data, preparation, review or approval of the manuscript or decision to submit the manuscript for publication.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Thijssen, E.H., Verberk, I.M.W., Vanbrabant, J. et al. Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease. Sci Rep 11, 9736 (2021). https://doi.org/10.1038/s41598-021-89004-x
Molecular Neurodegeneration (2021)